Abstract: Disclosed in the present invention is an eye drop for treating eye dryness. With a pH value of 5.0-7.0, the eye drop comprises the following components in percentage by weight: 0.05-0.1% of an active component 5-hydroxy-1-beta-D-furanosyl-1H-imidazole-5-carboxamide, an appropriate amount of a pH regulator, 0.01-3% of an isotonic agent, 0.003-0.5% of a bacteriostatic agent, 0.001-0.5% of a stabilizer, 0.01-0.5% of a tackifier, 2-5% of a solubilizer, and the balance of water. The eye drop provided by the present invention can protect the epithelial barrier function of the corneas of mice with eye dryness, increase the number of goblet cells of the corneas, and achieve relatively good anti-inflammatory and immunosuppressive effects.

Abstract: A method of treating cancer in vivo includes introducing in vitro into human mesenchymal stem cells (hMSCs) at least one type of inhibitory oligonucleotide, and contacting a tumor tissue of syncytial cancer cells with the hMSCs in vivo under conditions permitting a hMSC to form a gap junction channel with a first syncytial cancer cell of the tumor tissue. As a result, the at least one type of inhibitory oligonucleotide is delivered into the first syncytial cancer cell by traversing the gap junction channel and the at least one type of inhibitory oligonucleotide is delivered into a second syncytial cancer cell of the tumor tissue by traversing a gap junction channel between the first syncytial cancer cell and the second syncytial cancer cell.

Abstract: The disclosure relates to compositions comprising a nucleic acid sequence having two domains: a cell targeting domain and a microRNA domain, wherein the cell targeting domain comprises an aptamer sequence that targets cancer cells and the microRNA domain comprises a microRNA sequence that binds to an endogenous mRNA sequence within a cancer cell and disrupts normal function of the cell.

Abstract: This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.

Abstract: The invention relates to topical formulations comprising: a galactooligosaccharide; 0.01% to 10% w/w xylitol; and a pharmaceutically or cosmetically acceptable carrier. The invention also relates to use of the formulations, and methods for their preparation.

Abstract: Provided herein are methods, compounds, and compositions for modulating expression of at least one member of the Notch signaling pathway in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a respiratory disorder associated with excessive mucus production in an individual.

Abstract: Methods of monitoring therapeutic efficacy in a subject with MDS are provided. Also provided is a method of identifying a subject with myelodysplastic syndrome (MDS) for treatment with a telomerase inhibitor, and methods of treating MDS. The subject methods can include administering to the subject an effective amount of a telomerase inhibitor and assessing the hTERT expression levels in a biological sample obtained from the subject. In some cases, a 50% or greater reduction in hTERT expression level identifies a subject who has an increased likelihood of benefiting from treatment with the telomerase inhibitor. The subject can be naive to treatment with a HMA, lenalidomide, or both. In some cases, the subject is classified as having low or intermediate-1 IPSS risk MDS and/or MDS relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA). In some instances, the telomerase inhibitor is imetelstat sodium.

Abstract: It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.

Abstract: An anti-inflammatory combination for improving nutrient metabolisms, intestinal functions and intestinal microecology and an anti-inflammatory food containing the anti-inflammatory combination are disclosed. The anti-inflammatory combination includes inulin, galacto-oligosaccharide, polydextrose, and a water-insoluble dietary fiber. Furthermore, a weight ratio of inulin, galacto-oligosaccharide, polydextrose and water-insoluble dietary fiber is 10-30:5-30:10-40:10-50. The anti-inflammatory food includes cereal flour, and the ratio of the cereal flour to the anti-inflammatory combination is 65-95:35-5. The anti-inflammatory combination is capable of reducing intestinal permeability, blood endotoxins, heavy metals and inflammatory factors, enhancing immunity, improving intestinal microecology and body biochemical indicators, and preventing chronic diseases.

Abstract: The present invention provides a synergistic anti-inflammatory composition comprising one more anti-inflammatory agents such as a steroid, non-steroidal anti-inflammatory drug (NSAID) or a cannabinoid in combination with one or more sulfated polysaccharides. The invention is further directed to a method of treating inflammation and inflammatory diseases using said synergistic composition.

Abstract: A method of treating and/or preventing aortic stenosis in a patient in need thereof comprises administering to the patient a therapeutically effective amount of sevelamer or a pharmaceutically acceptable derivative, mixture or salt thereof (e.g. sevelamer hydrochloride or sevelamer carbonate). The method may attenuate or arrest the deposition of calcium phosphate crystals on the aortic valve of the patient. The method is applicable to patients who do not have hyperphosphatemia, including those having a serum phosphate level of 2.5 mg/d L to 4.5 mg/d L.

Abstract: In various embodiments, the present application teaches numerous compositions that include water clusters and methods of use thereof. In some embodiments, the present application teaches compositions and methods for treating, preventing and promoting the prophylaxis of bacterial infections in plants and animals. The present application further teaches compositions and methods for treating the surfaces of non-living substrates upon which bacteria are known or thought to reside. The present invention also teaches methods for adding compositions that include water clusters to foods and feed.

Abstract: The present invention relates to low concentration synergistic Xenon-Argon gas mixtures argon for use in a method for preventing and/or treating ischemic insults, wherein—the volume proportion of xenon is between 5 and 20%;—the volume proportion of argon is between 5 and 20%; and—the pharmaceutical composition further comprises a gas complement to reach 100% volume proportion;—the method includes comprises restoration of blood flow and the gas mixture is administered to the patient before, during, or after blood flow restoration.

Abstract: A topical application of nitric oxide may be provided by two separate containers, each containing an active component media to produce nitric oxide when combined. For example, a nitrite component media may be contained in one dispenser and an acidified component media may be contained in another dispenser. Each dispenser may dispense the respective component media as a foam. The resultant foams are combined to initiate the production of nitric oxide and the mixture of foams is applied topically to treat various skin disorders or wounds.

Abstract: The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.

Abstract: The present invention may comprise stabilized metal nanoparticles that are stabilized with material from gum arabic. The nanoparticles of the invention may be manufactured with an environmentally friendly method for fabricating biocompatible stabilized metal nanoparticles. The coated metal nanoparticles may be introduced in vivo to conduct therapy for humans or animals.

Abstract: Methods are provided for identifying whether a tumor, and especially a lung tumor, will be responsive to treatment with a therapeutic regimen that contains a platinum-based agent such as cisplatin and optionally contains a taxane. A specific Schlafen family member 11 (SLFN11) fragment peptide is precisely detected and quantitated by spectrometry directly in lung cancer cells collected from lung tumor tissue obtained from a cancer patient. Comparison to reference levels determines if the cancer patient will respond positively or negatively to treatment with the chemotherapeutic agents taxane plus a platinum-based agent such as cisplatin.

Abstract: Colloidal silver particles and cannabinoids are incorporated into emulsions and other compositions that find use, for example, as pharmaceutical and dermatological serums, creams, lotions and ointments.

Abstract: Disclosed are methods, compositions, devices, and kits for the isolation of brain-specific exosomes. Specifically, methods, compositions, devices, and kits comprising an isolated brain-specific extracellular vesicle or exosome joined to a first binding agent that is specific for tau, ?-amyloid, S100 ?, neuron-specific enolase, glycoprotein A2B5, CD133, NQ01, synaptophysin, neuronal nuclei, MAB1569, polysialic acid-neural cell adhesion molecule (PSA-NCAM), or neurogenic differentiation 1 (NeuroD or Beta2), or glycosylated or phosphorylated forms of these molecules, are provided.

Abstract: A method of treating a respiratory viral infection in a mammal is provided. The method comprises administering to the mammal a therapeutically effective amount of alveolar-like macrophages, or an anti-viral factor produced by alveolar-like macrophages.

Abstract: Systems and methods for treating lipid-related diseases including xanthomas, carotid artery stenosis (CAS), and cerebral atherosclerosis (CA) and their complications use direct visualization or imaging techniques to assess the state of the anatomy at issue. A high density lipoprotein composition is made and administered to a patient in order to treat those lipid-related diseases. The administration is continued for a predetermined time or until certain anatomical changes are observed based on imaging, biomarker, or biopsy analysis.

Abstract: Provided herein are methods of treating merkel cell carcinoma. The methods include selecting a subject having merkel cell carcinoma and administering to the subject a therapeutically effective amount of NK-92 cells, wherein administration treats the merkel cell carcinoma in the subject.

Abstract: Systems, compositions, and methods for the treatment of a liver disorder is disclosed. The systems, compositions, and methods include use of activated T regulatory cells for alleviating, treating, or reducing a liver disorder. The T regulatory cells may be allogeneic T regulatory cells that may be present in an amount of about 5×105 to 2×106 cells. The liver disorder needing treatment may be hepatitis, cirrhosis, chronic liver disease, acute liver disease, or liver failure.

Abstract: The present invention relates to the field of cancer therapy. More specifically, the present invention provides methods and compositions useful for augmenting anti-tumor immunity. In one embodiment, a method for treating or preventing post-allogeneic transplant relapse in a subject who has received post-transplant cyclophosphamide treatment comprises the steps of (a) obtaining a bone marrow sample from the subject; (b) expanding the marrow infiltrating lymphocytes (MILs) present in the sample; and (c) administering the MILs to the subject. In a specific embodiment, the method significantly reduces the likelihood of developing GVHD.

Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The purpose of the present invention is to provide a therapeutic agent for dilated cardiomyopathy disease which produces excellent effects in the treatment of dilated cardiomyopathy (DCM) and provides a given benefit to a large number of patients. The present invention is a therapeutic agent for dilated cardiomyopathy comprising at least one selected from the group consisting of mesenchymal stem cell and microparticles derived from the mesenchymal stem cell. It is preferable that the mesenchymal stem cell is a cell having the ability to contain or secrete microparticles, that the microparticles have an average particle size of 1000 nm or less, and that they are exosomes.

Abstract: Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.

Abstract: An acellular soft tissue-derived matrix includes a collagenous tissue that has been delipidated and decellularized. Adipose tissue is among the soft tissues suitable for manufacturing an acellular soft tissue-derived matrix. Exogenous tissuegenic cells and other biologically-active factors may be added to the acellular matrix. The acellular matrix may be provided as particles, a slurry, a paste, a gel, or in some other form. The acellular matrix may be provided as a three-dimensional scaffold that has been reconstituted from particles of the three-dimensional tissue. The three-dimensional scaffold may have the shape of an anatomical feature and serve as a template for tissue repair or replacement. A method of making an acellular soft tissue-derived matrix includes steps of removing lipid from the soft tissue by solvent extraction and chemical decellularization of the soft tissue.

Abstract: The present invention relates to an implantable therapeutic delivery system, methods of treatment utilizing the implantable therapeutic delivery system, and methods of fabricating the implantable delivery system.

Abstract: Disclosed are methods of lyophilizing a tissue sample comprising obtaining a tissue sample, contacting the tissue sample with a lyoprotectant solution, freezing the tissue sample, performing a first drying step of the tissue sample after freezing, and performing a second drying step of the tissue sample after the first drying step. Disclosed are lyophilized tissues prepared using the disclosed methods of lyophilizing a tissue sample comprising obtaining a tissue sample, contacting the tissue sample with a lyoprotectant solution, freezing the tissue sample, performing a first drying step of the tissue sample after freezing, and performing a second drying step of the tissue sample after the first drying step. Disclosed are methods of treating a wound or tissue defect comprising administering a reconstituted lyophilized tissue to the wound or tissue defect.

Abstract: Disclosed herein are methods and apparatuses for the safe, high-yield collection of sterile amniotic fluid. The apparatus are configured to allow sufficient flexibility for the device to gain access to all areas of the amniotic cavity, to allow sufficient stiffness for the amniotic fluid collection device to puncture the amniotic and chorionic membranes, yet allow sufficient suppleness to pose no significant risk of maternal or fetal harm. Further disclosed are cells isolated from the full-term amniotic fluid, and methods for using, reprogramming, and differentiating these cells.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.

Abstract: With the aim of proving an antibacterial composition against oral bacteria and the like capable of inducing Th1 cell proliferation or activation in an intestinal tract, the present inventors have found out that bacteria that suppress colonization and the like of the oral bacteria and the like in the intestinal tract are present in an intestinal microbiota. Moreover, the present inventors have succeeded in isolating intestinal bacteria that suppress intestinal colonization and the like of oral bacteria and the like.

Abstract: Ammonia oxidizing microorganism preparations for delivery to the visual and auditory systems, kits including ammonia oxidizing preparations for delivery to the visual and auditory systems, and devices for administering ammonia oxidizing preparations to the visual and auditory systems are provided. Methods of introducing ammonia oxidizing microorganisms to the eye are provided. Methods of introducing ammonia oxidizing microorganisms to the ear are provided. Methods of treating disorders, including eye disorders, ear disorders, and inflammatory disorders, with ammonia oxidizing microorganism preparations are provided.

Abstract: Provided herein are compositions and methods for the treatment of allergy, such as food allergy. Also provided herein are compositions and methods for modulating an immune response associated with allergy and/or inducing immune tolerance or desensitization to an allergy, such as a food allergy.

Abstract: The invention provides compositions comprising bacterial strains for treating and preventing a neurodegenerative disorder.

Abstract: Provided is a composition containing microorganisms derived from a living body with which more rapid and more reliable engraftment effect is achieved irrespective of the administration method and the administration route. A composition containing microorganisms derived from a living body, comprising (I) to (III) below is provided. (I) At least one or more types of microorganisms. (II) A solvent. (III) Nano-sized or smaller gas bubbles.

Abstract: A nutrient-germinant composition to aid in spore germination and a method for increased spore germination efficiency. The composition comprises L-amino acids, D-glucose and/or D-fructose, a phosphate buffer, an industrial preservative, and may include bacteria spores or they may be separately combined for germination. The method comprises providing a nutrient-germinant composition and bacteria spores, preferably of one or more Bacillus species, and heating to a preferred elevated temperature range of 41° C. to 44° C. for an incubation period of around 2 to 60 minutes. The nutrient-germinant composition is preferably in a concentrated liquid form that is diluted just prior to initiating the germination/incubation method at the point of use. The method may also include dispensing a germinated spore solution to a point-of-use/consumption, such as animal feed, water, or bedding, or a wastewater system or drain.

Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications.

Abstract: The present invention relates to a composition comprising or, alternatively, consisting of an effective amount of a mixture comprising at least one bacterial strain, and/or derivatives thereof, belonging to the species Lactobacillus salivarius, for the curative or preventive treatment of neurodegenerative diseases, such as Parkinson's disease.

Abstract: This invention provides for a dry preserved formulation of Lactobacillus suitable for administration to people as a pro-biotic or live biotherapeutic treatment where the formulation is stable, has high potency, and contains no animal-derived excipients.

Abstract: The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof, use of the same for medical or non-medical applications, kits, bandage, and wound dressing comprising the same.

Abstract: The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF). The method includes administering, to an individual, a composition including adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin I2 (PGI2).

Abstract: Recombinant herpes simplex viruses are provided having a modified oncolytic herpes virus genome, wherein the modified herpes virus genome has at least one miRNA target sequence operably linked to a first or to a first and a second copy of an ICP34.5 gene. Also provided are pharmaceutical compositions having such recombinant herpes simplex viruses, as well as methods of using such compositions in the treatment of subjects having cancer.

Abstract: An antibacterial essential oil includes 100 parts by weight of a Juniperus chinensis extract, 30 to 70 parts by weight of an Aquilaria agallocha extract, 30 to 70 parts by weight of camellia oil, and 10 to 40 parts by weight of a Dendropanax morbifera extract. Additionally, the antibacterial essential oil includes 10 to 40 parts by weight of a Portulaca oleracea extract, and 10 to 40 parts by weight of a Houttuynia cordata extract, 10 to 40 parts by weight of a Salicornict herhacea extract, and 10 to 40 parts by weight of a licorice extract. Further, the antibacterial essential oil includes 10 to 40 parts by weight of an Arctium lcwixt tea extract, 10 to 40 parts by weight of a jujube extract, 10 to 40 parts by weight of a Paeonia japonica extract, and 10 to 40 parts by weight of a Chamaecyparis obtuse extract.

Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.

Abstract: The present disclosure relates to a composition for preventing or treating metabolic diseases, the composition containing Artemisiae capillaris Herba and Citrus unshiu Peel complex extracts as active ingredients. Specifically, in the Artemisiae capillaris Herba and Citrus unshiu Peel complex extracts according to the present disclosure, the content of ingredients useful for prevention of metabolic diseases including obesity is much higher than in extracts obtained only from Artemisiae capillaris Herba. In addition, when a high-fat diet mouse model is administered the complex extracts, the levels of total cholesterol, LDL, and triglycerides in the blood are reduced. Accordingly, the complex extracts of the present disclosure may be used as a composition or functional material for preventing or treating metabolic diseases including obesity, hyperlipidemia, and hypercholesterolemia.

Abstract: The present invention relates to a composition for treating benign prostatic hyperplasia and a health functional food, containing an extract of Aucklandiae Radix and costunolide as active ingredients.

Abstract: Disclosed is a composition for preventing, ameliorating or treating visceral fat obesity containing a Salvia miltiorrhiza radix extract having excellent activity of reducing visceral fat. Disclosed is a composition for preventing, ameliorating or treating visceral fat obesity containing an extract of Salvia miltiorrhiza radix that has efficacy specific for visceral fat when administered to obese model animal mice that have obesity caused by decreased leptin secretion and diet-induced obesity (DIO) mice in which obesity is induced using a high-fat diet. Disclosed is a composition for preventing, ameliorating or treating visceral fat obesity containing an S. miltiorrhiza extract, wherein the S. miltiorrhiza extract inhibits the production of triglyceride (TG) in liver tissue and the blood, indicating that the S. miltiorrhiza extract has inhibitory activity on visceral-fat-type obesity, and the S.